This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

BARDA Continues Support Of Flublok® And Panblok® Influenza Vaccines

PEARL RIVER, N.Y., Feb. 15, 2013 /PRNewswire/ -- At a press conference today showcasing Protein Sciences' newly leased manufacturing facility for Flublok, the Company announced that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, will continue to support the Company's influenza vaccines program.  BARDA held an internal review of the Protein Sciences program and made a decision to modify its contract with the Company to support certain activities associated with scaling up manufacturing to meet the capacity metrics in the contract and to be able to expand the age indication of Flublok and Panblok influenza vaccines.  Flublok is a revolutionary new seasonal influenza vaccine that was granted U.S. FDA approval in January for use in adults 18-49 years old.  The Company expects to have approval for use of Flublok in people 50 years and above in time for the 2013/14 influenza season.  Flublok's sister vaccine, Panblok, is being developed to protect against pandemic influenza.  Protein Sciences and BARDA entered negotiations to provide additional support for the establishment of Flublok large-scale manufacturing in Pearl River, NY and help fund clinical studies required to secure FDA approval of Flublok for use in populations not included in the initial approval.  Thirteen new employees have already been hired to begin operations in Pearl River, and the Company plans to add approximately 30 more within the next year.

"We are pleased that BARDA has continued their commitment to support our influenza vaccine program," said Manon Cox, CEO of Protein Sciences.  "We could not have brought Flublok to market without their support, and their continued commitment will enable us to provide more doses of this important vaccine to more people in less time and to develop Panblok as an effective vaccine against pandemic influenza."  

Flublok and Panblok are the world's first recombinant vaccines for the prevention of influenza.   They are made using Protein Sciences' egg-free BEVS technology, a platform that enables rapid production of vaccine without the use of live influenza virus, an important feature in the face of a pandemic.  Protein Sciences' Pearl River facility will enable large-scale production of either vaccine depending on need. 

Today's conference marked one of the first occasions where Flublok was available for immunization of the public.      

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,772.72 -3.71 -0.02%
S&P 500 1,972.47 -14.58 -0.73%
NASDAQ 4,713.0360 -68.2280 -1.43%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs